Introduction
The present review will cover recent clinical advances in gene therapy for primary immune deficiencies, including the X-linked and adenosine deaminase (ADA)-deficient forms of severe combined immune deficiency (SCID), SCID-X1 and ADA-SCID, chronic granulomatous disease (CGD) and Wiskott-Aldrich syndrome (WAS). We will briefly review the historical background to the recently published and currently ongoing trials of gene transfer for these illnesses. We will also discuss the current problems facing clinical gene therapy and some of the preclinical work that may address these issues.
Recent advances in clinical gene therapy
In less than 20 years, the application of gene therapy in primary immune deficiency has gone from minimal success to a potentially completely curative procedure, albeit one with substantial risks. Earlier gene therapy trials conducted in the 1990s for ADA-SCID [1] , CGD [2] and leukocyte adhesion deficiency type I (LAD I) [3] did not achieve long-lasting clinical benefits. However, following on the technical advances achieved through extensive preclinical studies [4] , subsequent trials culminated in the first irrefutably successful result of a gene therapy protocol, described in the 21st century.
Successful gene therapy trials for X-linked severe combined immune deficiency
The first successful clinical gene therapy trial was reported by Cavazzana-Calvo et al. in 2000 [5] . This initial report described two patients with SCID-X1 due to a deficiency of the gc cytokine receptor. No myelosuppressive preparatory regimen was used. Additional data from this trial were reported in 2002 [6] , 2003 [7] and 2007 [8 ] . Overall, 10 patients with classic SCID-X1 were treated and long-lasting immune reconstitution was achieved. Most of the patients derived clinical benefit. Signs and symptoms of infection were resolved. T-cell counts, proliferative responses and diversity were normalized. All patients had proviral integration Purpose of review To discuss new data on the safety and efficacy of the ongoing gene therapy trials for primary immune deficiencies, the first reports of new trials and the preclinical developments that are likely to be translated to the clinic in the near future.
Recent findings
Both clinical successes and severe adverse events continue to be reported in trials of gammaretroviral gene therapy for severe combined immune deficiency-X1, adenosine deaminase-deficient forms of severe combined immune deficiency and chronic granulomatous disease. Insertion site analyses of recently reported trials on all of these diseases have discovered preferential insertion in the 5 0 ends of genes, including potentially dangerous ones such as proto-oncogenes and signal transduction and proliferation genes. Preclinical work on rodent and canine models has tested novel vectors, including lentiviruses and foamy viruses. Summary Gene therapy for the most common forms of severe combined immune deficiency can lead to immune reconstitution in most patients, although a minority of patients has derived minimal clinical benefit and some have suffered severe adverse events including death. Ongoing preclinical work attempts to address the latter shortcoming. Meanwhile, in the presence of a careful risk-benefit assessment, gene therapy remains an appropriate subject of clinical investigation.
Keywords clinical trials, gene therapy, insertion site analysis, insertional oncogenesis, primary immunodeficiency in approximately 100% of their T cells. Most of the successfully treated patients had normal levels of immunoglobulin (Ig)G, IgA and IgM. One of the two patients who did not achieve immune reconstitution was a 10-month-old boy with disseminated bacille CalmetteGué rin (BCG) infection and splenomegaly [6] . This patient ultimately required allogeneic hematopoietic cell transplantation (HCT).
The potentially curative outcome of gene therapy for SCID-X1 was confirmed by Gaspar et al. [9] in Great Britain. They reported successful reconstitution of immunity in 10 patients with classic SCID-X1. As of the last full report, all patients showed increased lymphocyte counts, most in the normal range. T-cell function and diversity were mostly normalized as well. Six patients no longer need intravenous immunoglobulin (IVIG). Taken together, the French and the British reports show, for the first time, clear efficacy of gene therapy for a human genetic disease and also point out some of the limitations of the approach, including the failure of gene therapy in two older patients (age 15-20 years) [10] .
Older patients who failed transplant were the targeted population of a recent United States trial evaluating the efficacy of gene therapy for SCID-X1 as a rescue therapy after a failed allogeneic HCT. In this report, a team of investigators from the National Institutes of Health described the treatment of three patients aged 10, 11 and 14 years. After a follow-up of 1-2 years, only one patient was found to have improvement in T-cell number and proliferation, along with an increased number of CD45RAþ T cells and T-cell receptor excision circles. No patient was able to discontinue IVIG, but all three reported subjective improvements in well-being, and all have shown increased growth rates [11] .
Overall, current experience indicates that, provided sufficient numbers of transduced hematopoietic stem cells (HSCs) are engrafted, gene therapy is a highly successful therapeutic modality for SCID-X1 infants, although its efficacy decreases in older patients.
Adverse events in the X-linked severe combined immune deficiency trials Unfortunately, despite successful results, the gene therapy trials for SCID-X1 highlighted the substantial risks of the procedure. About two and a half years after treatment, the fourth patient treated in the French trial developed a monoclonal lymphoproliferation caused by the insertion of the therapeutic vector near LMO2, a known T-cell oncogene. Dysregulation of LMO2 induced by the murine leukemia virus (MLV) enhancer was concluded to be the basis of the leukemic event in this patient and in a second case that occurred shortly thereafter [7, 12] . Over the last five years, additional reports have described other patients with T-cell lymphoproliferations [7, [12] [13] [14] [15] (www.asgt.org). Two of the patients were very young (1 and 3 months of age at the time of gene therapy, respectively) and received cell doses in excess of 10 million cells/kg. Very young age, however, was not common in all of the patients with leukemia [13, 16 ], (www.asgt.org). Overall, as of the last reports, 20 classic SCID-X1 patients have been treated in the French and British versions of this trial. Three of these patients had poor immune reconstitution and one of them died after allogeneic HCT. Five patients developed leukemia and one of them died as well [17] . Thus, the overall mortality was 10% and the overall morbidity 30%.
The question of why five out of 20 patients treated in the French and British SCID-X1 trials developed leukemia is one of the most pressing current problems in clinical gene therapy. Some controversy exists over the relative roles of either IL2RG or LMO2 or their combination in leukemogenicity [14, [18] [19] [20] 21 ]. A recent report noted that, in addition to frequently integrating near the 5 0 ends of genes, the vector used in the French trial preferentially integrated into common fragile sites [22] . Because LMO2 itself is a fragile site, this finding may help in explaining why targeting of this particular oncogene was seen so frequently. In addition to these considerations, it is generally accepted that the preference of retroviral vectors for integration in gene-rich regions [23, 24] , and particularly near the transcriptional start sites of genes, has likely contributed to severe adverse events. Recent surveys of clinical samples from the British and French SCID-X1 trials [8 ,16 ] have confirmed this tendency, a finding that was described earlier in vitro and in experimental animal systems [23] [24] [25] [26] .
Success of gene therapy for adenosine deaminasedeficient forms of severe combined immune deficiency Uniquely among the primary immunodeficiencies, ADA-SCID can be treated with enzyme replacement therapy (ERT) using pegylated bovine ADA (PEG-ADA) [27] . Early trials of gene therapy for ADA-SCID [1, 28, 29] treated patients who, for ethical reasons, were kept on PEG-ADA. The initial attempts at targeting HSCs resulted in low transduction efficiency [28, 30, 31] and low engraftment of gene-corrected cells [29] .
In a landmark study published in 2002, Aiuti and colleagues [32] treated ADA-SCID patients who did not have access to PEG-ADA with low-dose busulfan prior to the infusion of autologous bone marrow CD34þ cells that had been genetically corrected using a retroviral vector, with a goal of facilitating the engraftment of corrected cells. The initial report convincingly showed that immunity could be restored with this approach. To date, data on 12 patients have been reported in various forms [32,33 ,34 ] and indicated long-term multilineage engraftment of gene-corrected cells, associated with improvement in T-cell counts and proliferation to exogenous stimuli, leading to clear clinical benefits. No serious adverse events have been observed in the trial. An extensive analysis of the pattern of retroviral integration in five patients has recently been published and showed that integrations have occurred within and/or near the LMO2, BLM, CCND2 and BCL2 genes, among others, although these events did not lead to clonal selection [33 ] .
The efficacy of these trials surpassed those of a concurrent collaborative trial conducted by our own group and that of Kohn [4] at Childrens Hospital Los Angeles (CHLA). The emphasis in this trial was on vector design. Patients were kept on PEG-ADA, and myelosuppressive chemotherapy was not used [35] .
A Japanese trial recently reported in abstract form [36] also did not use marrow conditioning but involved discontinuation of PEG-ADA before the reinfusion of gene-corrected cells. Patients in this trial showed a slow immunological improvement compared with the Milan study.
The initial results of a British study [37] on gene therapy for ADA-SCID, that also included withdrawal of PEG-ADA as well as myelosuppressive chemotherapy, were published in 2006 and showed immune recovery manifested by increasing T-cell numbers and T-cell proliferative responses in the first treated patient.
More recently, our own group has used a similar protocol with PEG-ADA withdrawal and low-dose myelosuppresive chemotherapy. Four patients with ADA-SCID have been treated with this approach to date. After administration of myelosuppressive chemotherapy and gene therapy, the first treated patient was discovered to have had bone marrow trisomy 8 that predated chemotherapy. The patient suffered from persistent myelosuppresion after chemotherapy and ultimately required hematopoietic stem cell transplantation [38] . Two other patients have been followed up for at least 10 months and remain off PEG-ADA treatment without opportunistic infection, and one of these is also off IVIG. The patients have shown general clinical improvement as well as improvement in T-cell counts and T-cell proliferative responses. Finally, a fourth child treated recently remains off PEG-ADA, but otherwise has not had enough time since treatment for the outcome to be evaluated [39] .
Recent data on gene therapy for chronic granulomatous disease and Wiskott-Aldrich syndrome
A recent trial on gene therapy for CGD was conducted by Grez and Seger in Germany and Switzerland. The retroviral vector used in this study carries gp91 phox under the control of the spleen focus forming virus long terminal repeat (LTR), a promoter that is highly active in myeloid cells. High levels of functionally corrected phagocytes were observed, resulting in a reduction in infections in three treated patients. Oligoclonal expansion of genecorrected myeloid clones was also observed in the first two treated patients. This was likely due to the insertional activation of the cancer-associated genes MDS1-EVI1, PRDM16 and SETBP1 [40, 41] . Recent findings from this trial indicate that both these patients developed monosomy 7, which was presumed to be related to these insertional events [42] . Clearly, these results raise serious concerns regarding the vector LTR used in this trial.
More recently, Malech and colleagues [2] have reported on the use of genetically modified cells to treat infections in CGD, rather than attempting immune reconstitution per se [43, 44] . Conditioning consisted of busulfan (10 mg/ kg) given over 2 days. One of the two treated patients had a resolution of multiple staphylococcal liver abscesses and retained 1% correction of myeloid cells for more than 1 year. The second patient was felt to have immunemediated rejection of the transgene product. This is now under investigation.
Finally, at the 2007 meeting of the American Society of Hematology, a preliminary report on a trial of retroviral gene therapy for WAS was given [45] . On the basis of prior optimization in vitro [46] , Klein and colleagues treated two patients, both of whom have derived clinical benefit from the procedure. Both patients' genetic marking is increasing in T cells and natural killer (NK) cells. No evidence of adverse events or clonal dominance has been noted in this trial to this time.
Implications of recent clinical results on preclinical development of gene therapy
The occurrence of severe adverse events in SCID-X1 gene therapy patients [13] has stimulated extensive preclinical research efforts aimed at reducing the risk of insertional oncogenesis in future applications of gene therapy to SCID-X1 and other primary immune deficiencies. The tendency of gammaretrovirus vectors to integrate near transcription start sites of transcriptionally active genes [8 ,16 ,23,24,26,33 ] and the intrinsic promoter-enhancing activity of retroviral LTRs are seen as critical risk factors. To overcome the latter, Thornhill et al. [47] have developed self-inactivating (SIN) gammaretroviral vectors for gene therapy of SCID-X1. SIN vectors lack the enhancer sequences of retroviral LTRs and are, therefore, expected to be less prone to activating promoters near the integration sites [48, 49] . However, these vectors necessarily require the use of an internal promoter, and this element must also need to be devoid of significant enhancer properties if ectopic expression of genes neighboring the integration site is to be avoided.
Vectors based on lentiviruses are an appealing alternative to gammaretrovirus vectors because their LTRs have no meaningful activity in the absence of the TAT transcriptional regulator, and their pattern of integration has been shown to be less biased toward transcription start sites [23] . At least one study [50 ] suggests that lentiviral vectors are less likely to integrate into sites related to cancer, cell growth or oncogenesis than MLV-derived vectors. For these reasons, lentiviral vectors are being developed and tested for a variety of primary immunodeficiencies, including the X-linked [51 ] , ADAdeficient [52, 53] and Artemis-deficient [54] forms of SCID, as well as CGD [55] and WAS [56, 57 ].
Vectors based on foamy virus [58] offer another alternative that is being evaluated for gene therapy of primary immunodeficiencies. Foamy vectors offer a number of advantages, including the observation that foamy virus is not known to be a human pathogen [58] and that the integration pattern of foamy viruses has been described as having a less strong preference for integrating near genes [25, 59 ] . Foamy vectors have been developed for gene therapy of LAD I [25] , a disease that has also been the object of efforts to increase the efficiency of retrovirus vectors in the canine model of the human condition [60, 61] .
Despite advances made in the above-mentioned viral vectors, all of them suffer from the drawback that their use requires gene addition. Such strategies are inherently less desirable than genetic repair approaches. Of the various approaches to genetic repair being studied [62] [63] [64] [65] , the zinc finger nuclease approach has been applied for SCID-X1 [66] as an example of a disease in which the strong selective advantage of gene-corrected cells could compensate for the low efficiency that at present characterizes all gene repair methods.
Conclusion
After extensive theoretical and preclinical work, human gene therapy for SCID was translated to the clinic in 1990. Within 12 years, this form of treatment was shown to be efficacious. This rapid and successful progress can be attributed to advances in vectorology, cell culture conditions and the use of preparative myelosuppressive therapy. Although still incompletely characterized, the risks associated with gene therapy for the primary immunodeficiencies remain high and warrant a careful analysis of the risk-benefit ratio. Preclinical and clinical advances continue to be made in the safety and efficacy of gene transfer vectors and gene correction approaches. Although it is likely that in the future, gene therapy for primary immunodeficiencies will evolve beyond the use of integrating vectors for gene addition approaches, integrating vectors currently remain the state of the clinical science. Carefully monitored clinical trials on gene therapy are appropriate for patients with these severe illnesses who lack a matched related donor. In some cases, gene therapy for immune deficiency has brought clinical benefit and can be considered to be life saving despite the serious complications that have been reported in some patients. On the basis of the documented clinical successes, further progress in the development of gene therapy for primary immune deficiency can be expected.
14 Pike-Overzet K, van der Burg M, Wagemaker G, et al. [8 ] . A revised frequency of common integration sites identified in this trial also suggests the existence of differences between the French and British transduction procedures.
